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Abstract
Introduction: Immune system dysfunction is considered to be one of many med-
ical disorders found in children with autism. The primary objective of the study
was to assess if blood tests reflecting humoral immunity (IgA, IgG, IgM, IgE) are
useful in identifying children with regressive autism. The secondary objective
was to evaluate a part of the cellular arm of immunity (CD4/CD25 Tregs,
CD4/CD23 cells) in those children. 
Material and methods: Using a clinical case-control design, the systemic levels
of immunoglobulins and lymphocyte subpopulations analysed by flow cytome-
try were compared in children aged 3-6 years old with a new diagnosis of regres-
sive autism (n = 24; mean age: 4.25 ±1.70 years; male 23/24) and in sex- and
age-matched healthy children (n = 24; aged 4.25 ±2.20 years; male 23/24). 
Results: The humoral immunity profile, described by three binary variables, 
IgA < 0.97 g/l, IgE > 36 IU/ml, and IgG > 6.3 g/l, with a sensitivity of 79% and
a specificity of 83% (p < 0.0001), was able to identify children with autism. The
highest risk of autism diagnosis was associated with IgA < 0.97g/l (OR – 23.0;
p < 0.001). A higher number of CD19/CD23 was found in children diagnosed with
autism than in the control group (36.82 ±6.72% vs. 18.20 ±3.95%; p < 0.02). No
correlation between the number of CD23-positive cells and serum IgE levels was
observed.
Conclusions: A subtle shift of serum immunoglobulins consisting of low-normal
IgA and B cell activation expressed by an increase of CD23-positive cells may
characterize children with regressive autism aged 3-6 years old. 
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Introduction
For many years reciprocal functional connections between the brain,
behaviour, and the immune system have been the subject of interest for
researchers [1, 2]. Numerous recent publications have focused on immune
dysfunction and autoimmunity in various neuropsychiatric disorders such
as schizophrenia, paediatric autoimmune neuropsychiatric disorders asso-
ciated with streptococcal infections (PANDAS), and obsessive compulsive
disorder [3, 4]. Immune dysfunction is also considered in the aetiology and
pathology of autism spectrum disorders (ASD) [5, 6]. 
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The autistic spectrum disorders are complex
developmental disorders and are a part of a broad
spectrum of neurodevelopmental disorders known
as pervasive developmental disorders. They are
diagnosed on the basis of clinical characteristics
(DSM-IV) [7]. The ASDs are characterized by impair-
ments in social interaction, deficits in verbal and
nonverbal communication, and the presence of
restricted and repetitive stereotyped behaviours.
They manifest within the first 3 years of life. ASDs
are an extremely heterogeneous group of disorders
with multiple phenotypes and subgroups which dif-
fer in the degree of behavioural disorders and vary
in the response to treatment. 
Immune system abnormalities in children with
autism include both enhanced autoimmunity and
reduced immune function. Immune abnormalities
reported in autistic children include abnormal
Th1/Th2 cytokine profiles, decreased lymphocyte
numbers, a decreased T cell mitogen response,
and an imbalance of serum immunoglobulin lev-
els [5, 8, 9]. In addition, autism has been linked
with autoimmunity and an association with
immune-based genes, including human leukocyte
antigen (HLA)-DRB1 and complement C4 alleles,
has been described [8]. Autoimmunity is charac-
terized by the presence of antibodies reactive to
central nervous system (CNS) proteins with the
potential for neuronal tissue destruction. These
antibodies also include those against neuron-axon
filament proteins (NAFP), cerebellar neurofila-
ments, myelin basic protein (MBP), the caudate
nucleus, serotonin receptors, brain endothelial
cells, as well as antibodies against tissue and spe-
cific antibodies targeted against gut epithelial
cells [6, 8, 10-12]. These findings lead some
researchers to treat autism as a chronic inflam-
matory disease of the brain with an origin in pre-
natal life [13].
According to recent findings, circulating mater-
nal autoantibodies directed toward fetal brain pro-
teins are highly specific for autism [14].
Other observations suggest activation of an aller-
gic process and warrant antiallergenic treatment
and elimination of certain foods from the diet of
children with autism [15, 16]. Immunological phe-
nomena associated with autistic disorders are not
yet fully understood. 
The primary objective of this study was to assess
if commonly available blood tests reflecting the
humoral immunity profile (IgA, IgG, IgM, and IgE)
are able to identify recently diagnosed children with
regressive autism. A secondary objective was to
investigate cellular immunity (lymphocyte subtypes,
CD4/CD25 T regulatory cells) in those children. Addi-
tionally, gluten-specific IgG in sera of children with
autism was assessed and compared to the sera of
healthy children. 
Material and methods
Subjects 
According to the study protocol a case-control
design was used. Children recently diagnosed with
autism were recruited from the Bialystok Branch of
the National Autism Society. The diagnosis of
autism was made in all subjects by a team of expe-
rienced psychologists and a psychiatrist according
to the diagnostic criteria for autism outlined in the
Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition, and the International Classifi-
cation of Diseases, Tenth Revision [7, 17]. Children
were recruited to the study from February 2009 to
April 2010. The medical history was gathered and
physical examinations were performed on all chil-
dren. The course of pregnancy, mode of delivery,
and general condition of the newborn after birth
were noted from personal health books. A medical
history for acute and chronic illnesses was collect-
ed from the parents. A family history of the atopic
triad – atopic dermatitis, allergic rhinitis, and
bronchial asthma – was included in the question-
naire. Body mass index (BMI) was calculated as
weight (kg) divided by height squared (m2). The
inclusion criteria for the study group were: 1) a new
diagnosis of regressive autism (children with regres-
sion who initially developed but subsequently lost
previously acquired language and/or social skills);
2) no pharmacological or dietary treatment as well
as no supplements within the last 6 weeks (in order
to avoid any potential influences on immunity such
as stimulating or inhibiting effects); 3) a negative
history of infection in the previous 6 weeks. 
One healthy child of the same age (3-6 years)
and sex was matched for each child with autism.
The place of residence (town/village) was taken into
account in matching participants to their groups.
Healthy children with normal development were
recruited from two preschools (town/village; 
n = 18/n = 6). The inclusion criteria for the control
group were the same as criteria 2 and 3 for the
autism group listed above. Participants were exclud-
ed if they had an acute infection or chronic dis-
eases, had taken medications, vitamins, or supple-
ments, or if dietary intervention or alternative
therapy was applied. Children for each case-control
pair were recruited in the same allergic season and
the time interval of the blood sample collection
from both (the case and the control) was no longer
than 4 weeks. None of the control children were
recruited from families with a history of ASD. All
study participants were Caucasian.
This study protocol followed ethical guidelines
and was approved by the Bioethics Committee of
the Medical University of Białystok. Informed con-
sent was obtained from the parents prior to par-
ticipation.
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Laboratory analysis
Blood samples were collected between 7 am 
and 9 am. Immediately after centrifugation the sera
were aliquoted and frozen at –80°C until assayed
for immunoglobulin levels. Serum IgG, IgM, and IgA
concentrations were measured using the nephelo-
metric technique (Siemens nephelometer BN II sys-
tem) with a detection range of 0.06-8.00 g/l for IgA,
1.4-45.0 g/l for IgG, 0.05-6.40 g/l for IgM. The ref-
erence range of serum immunoglobulins for chil-
dren aged 3 to 6 years in the children’s hospital lab-
oratory are: IgA 0.36-2.40 g/l, IgG 5.0-13.2 g/l, IgM
0.46-1.75 g/l, IgE 0-85 IU/ml. Serum IgA levels less
than 7 mg/dl (0.07 g/l) were accepted as diagnos-
tic of selective IgA deficiency and levels at least 
2 SD (standard deviations) below normal for age
were diagnostic of partial IgA deficiency [18]. Total
IgE and gluten-specific IgG (f79) were detected
using the UniCAP fluoroenzymeimmunoassay (Phar-
macia, Sweden) according to the manufacturer’s
instructions. The reference range of IgE in the lab-
oratory for children 3-4 years of age is 0-33 IU/ml,
and for children ≥ 5 years of age is 0-85 IU/ml.
Serum hsCRP and serum tumour necrosis factor α
(TNF-α) were measured using a commercially avail-
able ELISA kit (Quantikine High Sensitivity Human
by R&D Systems, Minneapolis, Minn., USA) and
according to the manufacturer’s instructions. 
Assessment of peripheral blood morphology. For
the assessment of the leukogram component, 2 ml
of venous blood was obtained in blood collection
tubes containing EDTA. A blood count analysis was
performed using automated haematology analyz-
ers (SYSMEX XT 2000i, Japan). Leukocyte count was
expressed in G/L and lymphocytes were expressed
as percentages (%). 
Assessment of the lymphocyte subpopulation in
peripheral blood. Cytometric analysis was per-
formed on the blood which remained after the mor-
phological assessment mentioned above. The fol-
lowing monoclonal antibodies were added in 10 μl
amounts to 100 μl of full blood (Beckman Coulter):
CD3-PC5, CD4-FITC, CD4-PC5/CD25-FITC, CD8-PE,
CD19-PC5, CD19-PC5/CD23-PE.
Statistical analysis
Student’s t-test was applied to compare vari-
ables of a normal distribution (gestational age, birth
weight, Apgar score, breastfeeding duration, BMI,
CRP, WBC, IgG, IgM). The Mann-Whitney U-test was
applied to compare variables of non-parametric dis-
tribution (IgA, IgE, gluten-specific IgG, peripheral
eosinophilia, lymphocyte subpopulations) and the
Shapiro-Wilk test to verify the statistical shape of
the tested variable distribution. Lastly, the χ2 test
for independence was applied to compare qualita-
tive and categorical variables. Spearman’s non-para-
metric rank correlation test was used to evaluate
the correlation between immunoglobulin levels, age,
WBC count and lymphocyte subset. Receiver oper-
ating characteristic (ROC) curves analysis was per-
formed to determine the most appropriate cut-off
points for the individual parameters: IgG, IgA, IgM,
IgE, WBC count, and absolute eosinophil count. The
cut-off values were used to transform continuous
data into binary (0,1) variables. These variables were
included in the logistic regression model to calcu-
late the probability of the accuracy of a diagnostic
value for a diagnosis of autism. Two-tailed p < 0.05
were considered statistically significant. MedCalc
was used for the ROC analysis, GraphPad Prism 5.0
was used for comparative analysis, and a logistic
regression model was created using Statistica 9.0
software.
Results
Table I shows the baseline characteristics of the
study participants. Both groups had a similar peri-
natal history and did not differ in physical charac-
teristics at the time of the study. Both were with-
out clinical or laboratory (hsCRP, TNF-α) signs of
infection. There was no difference in the white
blood cell count in the studied groups of children
although a tendency to have a higher peripheral
eosinophil count (p = 0.08) was observed in chil-
dren with autism. A comparison of immunoglobu-
lin levels is presented in Figure 1. Median and
interquartile range (IQR) of serum IgA was lower in
children with autism compared to the controls (0.82
g/l [0.61-0.95] vs. 1.43 g/l [0.80-1.62]; p < 0.012).
None of the children fulfilled the criteria of IgA defi-
ciency or partial IgA deficiency. Lower serum IgA
levels were associated with a higher white blood
cell count (r = –0.50, p < 0.01) in children with
autism but not in healthy children. Median and IQR
levels of IgE were higher in the sera of children with
autism although the difference was not significant
(Table I). IgE levels above the upper limit for age
were noted in 12/24 (50.0%) children with autism
and in 5/24 (20.8%) of the healthy children 
(p = 0.035). In healthy children the total serum IgE
level showed a correlation with age (r = 0.59, 
p < 0.05) but not in children with autism. 
The groups did not differ in mean serum IgM lev-
els (0.96 ±0.33 g/l vs. 0.86 ±0.23 g/l) or serum IgG
levels (9.02 ±1.78 g/l vs. 8.75 ±2.62 g/l). The values
of both immunoglobulins were within the reference
standards for age. The subclass of IgG containing
gluten-specific IgG was comparable in both groups.
Diagnostic accuracy was determined by area
under curve (AUC) from receiver operating charac-
teristic (ROC) analyses. The cut-off values for the
respective variables are presented in the table with
the results of the ROC analyses (Table II). The
humoral immunity profile, described by three bina-
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ry variables, IgA < 0.97 g/l, IgE > 36 IU/ml, and IgG
> 6.3 g/l, with a sensitivity of 79% and a specifici-
ty of 83% (p < 0.0001), was able to identify children
with autism (Table III). The highest risk of autism
diagnosis was associated with IgA < 0.97 g/l (OR –
23.0; 95% CI 3.41-159.00; p < 0.001). 
Mean values (95% CI) of peripheral blood lym-
phocyte subpopulations in the examined groups of
children are shown in Table IV. The groups did not
differ in white cell counts, in number of CD3, CD4,
CD8, CD19, NK, T regulatory cells (CD4/CD25), or in
the CD4/CD8 ratio. Children diagnosed with autism
differed in having a higher number of CD19/CD23
from children in the control group. No correlation
between the number of CD23-positive cells and
serum IgE levels was observed.
Discussion
It was found that autistic children between 3 and
6 years old differed in the humoral immunity pro-
file and B cell activity from healthy age-matched
controls. The pattern of serum immunoglobulins in
children with autism included three components:
IgA < 0.97 g/l, IgE > 36 IU/ml, and IgG > 6.3 g/l. The
immunoglobulin levels analysed together had high-
er sensitivity and specificity and were more able to
distinguish children with autism from their healthy
peers than specific immunoglobulins considered
separately. Of these 3 components, IgA had the
most important contribution in the humoral immu-
nity profile in children with autism.
A recent study estimated that serum IgA was
lower in children with autism than that found in
age- and sex-matched controls even though none
of the children fulfilled the criteria of IgA deficien-
cy or partial IgA deficiency. In healthy children the
production of IgA matures gradually; at the age of
12 months the level of IgA in the serum accounts
for about 20% of the adult value and at approxi-
mately 10 years of age reaches adult levels. The age
of the studied patients did not exceed 7 years;
therefore, the maturation process of IgA production
could not have been completed and it could be sus-
pected that this process may be slower in children
with autism compared to healthy children. Simi-
larly, other authors’ observations suggest that IgA
in children with autism may be within the lower
limits of normal or slightly below and that the
prevalence of autism is low in the IgA deficient
group [19, 20]. However, Warren et al. described IgA
deficiency in a subset of patients with autism and
found that the IgA deficit is associated with HLA-
DR antigens [21]. 
Impaired humoral immunity manifested as low
IgA may be associated with disorders of the gas-
trointestinal tract such as colonization with anaer-
obic bacteria and gastrointestinal symptoms includ-
ing abdominal pain, bloating, diarrhoea, and
constipation [8]. These types of gastrointestinal
symptoms are described in 9.0-84.1% of children
with autism compared to 9.0-37.0% of children
without autism [22]. Although most truly IgA-defi-
cient children have no clinical problems, children
with the symptomatic form may suffer from diar-
rhoea, otitis, sinusitis, autoimmune diseases or
atopic diseases. Another medical aspect of the mat-
urational delay in IgA is that it may be associated
in some children with non-IgE-mediated food aller-
gies [23]. 
In this study, total serum IgE in children with
autism was higher than in healthy children, but the
difference did not reach the significance threshold.
Parameter Autism Control  Value of p
groupg roup
(N = 24) (N = 24)
Age [years] 4.25 ±1.70 4.25 ±2.20 NS
(95% CI) (3.5-4.9) (3.3-5.1)
Male, n (%) 23 (95.8) 23 (95.8) NS
Urban residence,  18 (75) 18 (75) NS
n (%)
Vaginal delivery/C.S. 19/5 21/3 NS
Gestational age  38.8 ±0.6 38.1 ±0.2 NS
at birth [weeks]
Birth weight [g]  3270 ±83 3491 ±32 NS
Apgar score  9.6 ±0.3 9.4 ±0.6 NS
Breast feeding  5.4 ±2.9 5.2 ±3.3 NS
duration [months] 
Familial atopy, n (%) 7 (29.2) 4 (16.7) NS
BMI [kg/m2] 15.4 ±0.8 16.7 ±1.6 NS
hsCRP [mg/l] 0.1 ±0.02 0.05 ±0.01 NS
TNF-α [pg/ml] 0.3 ±0.0 0.2 ±0.0 NS
WBC [cells/μl]  8.0 ±2.3 6.9 ±1.7 NS
(95% CI) (7.0-9.1) (6.2-7.7)
IgA [g/l]  0.815 1.43 0.012
Median (IQR) (0.61-0.95) (0.80-1.62)
IgE [g/l]  41.0 20.0 NS
Median (IQR) (12.0-136.5) (9.0-36.5) (0.08)
Blood eosinophils  220.5 159.0 NS
[cells/μl] 
Median (IQR) (125.6-334.3)(107.1-202.3) (0.08)
% WBC 3.4 ±2.7 2.2 ±0.8
Patients with  9 3 0.047
eosinophilia > 3%
IgG Gluten [mgA/l] 4.0 5.3 NS
Median (IQR) (2.53-7.64) (3.53-7.04)
Table I. Baseline characteristics of study participants
C.S. – caesarean section, BMI – body mass index, WBC – white blood
cells, TNF-α – tumour necrosis factor α
Values are mean (± SD) unless otherwise stated, IQR – interquartile
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However, serum IgE levels above the reference
range for age were significantly more common in
the group of children with autism than in the con-
trol group (50.0% vs. 20.8%). IgE was also entered
as a significant variable in the logistic regression
model. Therefore, it appears that at least for some
children with autism serum IgE levels may have clin-
ical significance. Also, Gupta found an increase in
IgE in 52.0% among 25 children with autism (13/25)
[24]. There are, however, studies in which there is
no increase in IgE in children with autism [9, 25].
Total IgE exceeding the norm may indicate an aller-
gic reaction but can be a sign of infection, autoim-
mune disease or the presence of cancer, as well as
occur in healthy people [26].
The results of this study raise the question of
whether there is a link between the reduction of
IgA and the increase of IgE. Overstimulation of the
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Figure 1. Comparison of serum immunoglobulin levels of IgA, IgE, IgG and IgM in children with autism (case) and in
healthy (control) children (mean with SEM, two-tailed p)
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Parameter Cut-off value Sensitivity (95% CI)S p ecificity (95% CI)A UC ± SE (95% CI)
Serum IgA [g/l] 0.97 66.7 (44.7-84.3) 79.2 (57.8-92.8) 0.681 ±0.077 (0.531-0.808)
Serum IgE [IU/ml] 36 79.2 (57.8-92.8) 58.3 (36.7-77.9) 0.646 ±0.08 (0.495-0.778)
Serum IgG [g/l] 6.3 20.8 (7.2-72.2) 95.8 (78.8-99.3) 0.635 ±0.08 (0.483-0.769)
Serum IgM [g/l] 1.08 87.5 (67.6-97.2) 33.3 (15.7-55.9) 0.586 ±0.083 (0.435-0.726)
Eosinophil count [cells/μl] 244.4 91.7 (73.0-98.7) 50.0 (23.1-70.9) 0.648 ±0.08 (0.496-0.780)
Table II. Receiver operating characteristics of serum immunoglobulin levels in distinguishing between children with
autism and control children – sensitivity and specificity for cut-off values of evaluated parameters
AUC – area under the ROC curve, CI – confidence interval, SE – standard error
Variables included in the  Regression  SE Wald  Value of p OR 95% CI for OR 
regression model coefficient statistic lower – upper
IgA< 0.97 g/l –3.151 0.095 10.903 0.00096 23.0 3.41-159.89
IgE> 36 IU/ml 2.233 0.922 5.861 0.01649 9.3 1.45-59.91
IgG> 6.3 g/l 2.924 1.388 4.438 0.03516 18.6 1.14-305.20
Table III. Logistic regression results with serum IgA, IgE, and IgG as the outcome variable 
OR – odds ratio
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IgE system because of a qualitative defect in IgA
production is a known phenomenon [27]. It can be
speculated that this could pertain to some of the
studied children. This concept, however, requires
further research. 
Sensitivity to food has been suggested as
a potential aetiological factor in childhood autism
[28]. An IgE-dependent allergy to food and envi-
ronmental antigens does not appear to be more
prevalent in children with autism [25, 29]. IgE-inde-
pendent reactions such as delayed hypersensitivi-
ty reactions are quite common [30]. In this study
the serum gluten-specific IgG levels were assessed
and the results were comparable in both groups.
A higher prevalence of atopy in families of children
with autism was not found; however, allergic 
disorders in the family and maternal autoimmune
diseases were found to be more common in chil-
dren with autism in other studies [28]. In the Croen
study, asthma and maternal atopy were more
strongly associated with autism in families with
more than one ASD-affected child, thus suggesting
that genes underlying atopy may also be aetiolog-
ically related to autism [31]. 
In a recent study, children with autism demon-
strated a tendency to have a higher percentage of
eosinophils among peripheral blood leukocytes. The
criteria to diagnose true eosinophilia were not ful-
filled; the upper confidence limit did not exceed the
reference value of 400/μl. The results of this study
are consistent with research by Renzoni et al. [29].
Eosinophilia in the patients did not correlate with
serum IgE and could possibly have been due to fac-
tors other than allergy. Eosinophilia as a nonspe-
cific symptom may be associated with such dis-
eases such as parasitic infestations, non-parasitic
infections, immune disorders, or endocrine diseases.
Recently, a boy with autism and eosinophilic
oesophagitis, which is a gastrointestinal disorder
that may present with peripheral eosinophilia and
increased serum IgE levels, was described [32, 33].
The IgG class antibodies are the basic antibod-
ies produced by the immune system in response to
foreign antigens. In this study no differences were
found in the serum levels of IgG between the chil-
dren with autism and the children in the control
group. Other authors’ observations pertaining to
IgG and IgM in children with autism are conflicting.
Heuer et al. described decreased levels of IgG and
IgM in children with autism and found that this
reduction correlated with behavioural severity [34].
Enstrom et al. observed a significant increase in IgG4
subclasses and Croonenberghs et al. found increased
IgG due to a rise in specific IgG subclasses IgG2 and
IgG4 in subjects with autism [35, 36]. The authors
note that the increased serum concentrations of
IgG in autism may point towards an underlying
autoimmune disorder. A family history of autoim-
mune disorders is more common among children
with autism than healthy control children [10, 37].
Some studies indicate that the cellular arm of
the immune system could be either activated or
abnormal in individuals with autism [38, 39].
A reduced number of T cells was not found and the
CD4/CD8 ratio was normal in this study. Lack of dis-
orders in major T cell subpopulations can be
explained by the young age of patients, short time
of disease duration, and a regressive form of autism
(regression after the period of normal development).
According to Warren et al., only children express-
ing the complete syndrome of autistic disorder had
significantly reduced numbers of both total T cells
and CD4 cells [40]. Treg cells are regarded as the
primary mediators of peripheral tolerance and play
a pivotal role in the pathogenesis of autoimmune
and immunosuppressive diseases. An increased
number of Tregs in the studied children was not
found.
In the current study, increased expression of
CD19/CD23 in children diagnosed with autism was
found. CD23 is a surface marker of activated B cells
as well as a low-affinity Fc receptor for IgE (Fc-Epis-
lon-RII) and is involved in the development of dif-
ferent kinds of diseases including, but not limited
to, allergy and inflammatory or lymphoproliferative
diseases (soluble CD23) [41]. CD23 is involved in the
regulation of IgE responses: IgE-mediated antigen
presentation, regulation of IgE synthesis, and dif-
Parameter Autism group Control groupV alue of p
(N = 24) (N = 24)
Mean ± SD Mean ± SD
(95% CI) (95% CI)
White cell  8.39 ±0.56 8.12 ±0.51 0.7210
count [G/l] (7.25-9.54) (7.06-9.17)
CD3  65.21 ±2.38 66.99 ±2.24 0.2605
(60.35-70.07) (62.36-71.34)
CD4 36.91 ±0.96 39.95 ±2.37 0.2699
(34.93-38.89) (34.91-45.00)
CD8  25.02 ±1.47 22.71 ±1.37 0.1466
(22.03-28.02) (19.85-25.56)
NK 10.57 ±0.83 9.24 ±1.18 0.3201
(8.88-12.26) (6.80-11.67)
CD4/CD8  1.85 ±0.30 1.99 ±0.20 0.7874
(1.24-2.46) (1.56-2.42)
CD4/CD25 10.55 ±2.10 8.09 ±1.15 0.3784
(6.13-14.97) (5.55-10.64)
CD19 18.66 ±1.02 19.41 ±2.37 0.8311
(16.57-20.76) (14.49-24.32)
CD19/CD23 36.82 ±6.72 18.10 ±3.95 0.0134
(22.89-50.73) (9.90-26.29)
Table IV. Lymphocyte subpopulations of peripheral
blood expressed as percentages in children diag-
nosed with regressive autism and in healthy children 
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ferentiation of B and T cells [42]. CD23 is known to
act as a negative regulator of IgE production and
its expression is low in allergic disorders such as
allergic rhinitis and allergic asthma [41, 43]. Mono-
clonal antibodies against the CD23 antigen inhibit
IgE production by B lymphocytes and decrease total
serum IgE [44]. Increased expression of CD23 in the
studied children diagnosed with autism corre-
sponded with no difference in total serum IgE lev-
el from children in the control group. This result,
therefore, cannot be linked with IgE production.
Moreover, a correlation between CD23 and serum
IgE level was not observed. The lack of a difference
in levels of serum TNF-α between both studied
groups can argue against a relationship between
increased expression of CD23 and inflammation in
those children. However, an isolated marker is
insufficient to make such a conclusion. Assessment
of other inflammatory indices, and especially meas-
urement of serum soluble CD23 (sCD23) concen-
trations, could provide more data to understand
the findings. sCD23 is implicated in the up-regula-
tion of IgE synthesis and elevated concentrations
of circulating sCD23 are commonly associated with
inflammatory or lymphoproliferative diseases, such
as rheumatoid arthritis, asthma, and chronic lym-
phoblastic leukaemia [45]. It would be interesting
to know if sCD23 correlates with serum IgE in chil-
dren with autism with elevated serum IgE. CD23 is
expressed on B-cells following cell activation by
antigens. The results of this study suggest that 
B-cell activation in children diagnosed with autism
takes place.
Immune system abnormalities reported in chil-
dren with an autistic disorder suggest that immune
factors may be involved in the initiation or the evo-
lution of neurological disorders [39]. This study con-
firms that children with autism can have a subtle
difference in the humoral and cellular immunity pro-
file at the moment of diagnosis than age-matched
controls. However, these results are not without
limitations, one being the number of subjects. This
is especially visible in the logistic regression as
a wide confidence interval for the odds ratio. Addi-
tionally, increasing the number of children in the
control group so that the case to control ratio is 
1 : 2 or more would have provided more informa-
tive results. 
In conclusion, although extreme deviations and
evident pathologies were not found, the pattern of
humoral and cellular immunity in the studied chil-
dren with autism can be described as low-normal
IgA and high-normal IgE with B-cell activation man-
ifesting as increased expression of a low affinity
receptor for IgE. An increased number of CD23-pos-
itive cells was not previously described in children
with autism. Identification of an antigen responsi-
ble for the increase of CD23 expression requires fur-
ther research. Irrespective of the cause, this subtle
shift of serum immunoglobulins and B-cell activa-
tion may be related to inflammatory or allergic reac-
tions and autoimmunity described in children with
autism. 
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